Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
about
Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group.Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimensAssessment of FIV-C infection of cats as a function of treatment with the protease inhibitor, TL-3Modeling antiretroviral drug responses for HIV-1 infected patients using differential equation modelsTreatment of CMV retinitis with intravitral ganciclovir in the HAART eraResistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integraseGenotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.Inhibition of human immunodeficiency virus replication by RD6-Y664, a novel benzylhydroxylamine derivativeDrug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sitesIn vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolatesDicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase.Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitroVisit-driven endpoints in randomized HIV/AIDS clinical trials: impact of missing data on treatment difference measured on summary statistics.Use of observational data in evaluating treatments: antiretroviral therapy and HIV.Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.Laryngeal pathology in the acquired immunodeficiency syndrome: diagnostic and therapeutic dilemmas.The use of combination antiretroviral therapy in HIV-infected patients.Changes in surrogate laboratory markers, clinical endpoints, and health-related quality of life in patients infected with the human immunodeficiency virus.Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS.Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk.Changing patterns of HIV related ocular disease.Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV.Evaluating supervised HAART in late-stage HIV among drug users: a preliminary report.Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy.Proposed initiatives for healthy children orphaned by AIDS.In vitro human immunodeficiency virus eradication by autologous CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells.The role of HIV-proteinase inhibitors.Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapyHepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study GroupShort-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy.Highly active antiretroviral therapy (HAART) and circulating markers of immune activation: specific effect of HAART on neopterinThe drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy.Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo AcidState Implementation of the AIDS Drug Assistance Programs.Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T-cell death.Human immunodeficiency virus pathogenesis: insights from studies of lymphoid cells and tissues.Malignant lymphatic and hematopoietic neoplasms mortality in Serbia, 1991-2010: a joinpoint regression analysis.The critical role of p38 MAP kinase in T cell HIV-1 replication.
P2860
Q24534187-E66698C0-9392-480D-A2AB-ED8EE7B45A46Q24534391-919326A1-8DAD-4078-9ADB-97700819F5D1Q24801797-681300AC-8173-4891-8A45-E4D51EAA2A83Q27015861-EB222C49-8685-498B-A5A2-6BE3450C2D50Q28262771-F9D0109E-C2AB-4B52-8148-B5EFB592EB87Q28368842-737D9A7F-4CAF-41AD-BD88-F56FA8A09C0FQ28369030-4E3AD986-747F-4E9C-8CEC-A4A306DC6E8CQ28376476-53E2FA93-ECDB-4621-8CC8-8DCA306A53EFQ28379086-38211461-C083-44E3-96DC-5E25AB22A410Q28379223-82799F86-7297-428E-BE8B-5AEEF9994DBEQ28379316-B9D8CCA7-F05D-4D24-A9E0-7849F61F0E53Q28379621-1801D0EA-B139-4B99-9C5E-9CFEF60272C7Q30579320-1F5007C5-BCE8-41D8-BC5D-F7722C3FBF20Q30969932-279E0535-FD08-47D0-8D6E-D86278A89FDBQ31106166-C70BE393-3C3A-4005-979A-4117187A8D7FQ33535891-2B56FB04-053B-4E9A-AE6A-69E269335586Q33543115-4B7E8811-0FF2-47EE-9E9D-387654E45118Q33583301-A7B1CE5E-7FE0-4F11-A5D4-8A2A2A312FF6Q33644248-CD6CCDB1-E16C-447B-B434-CD933AB6C116Q33697958-3F828433-4697-4DC2-847B-3534F1907010Q33711640-FC98A720-D4E1-498A-806F-CA38EF0C9268Q33786404-98D17FDA-5F45-40D6-BD3A-00E37927EFF9Q33803069-7EE0329D-CC6B-48B7-B229-B08075A55A70Q33804495-5B7453B9-0B10-4900-BA6E-21627233FFB2Q33806165-A329C56C-9A61-4663-B223-8F4EE19E36C4Q33808633-0E1CBC58-38AC-4AC7-BEB3-5E546374DC4DQ33845018-CC56DFE6-65A3-48D1-9D14-8CC953309FCDQ33936186-4AF72364-12E3-474A-9EE7-757CD70AB68AQ33971104-5D03F978-8ED1-4E21-8287-D94585FE8785Q33981058-E26F946D-D61D-459F-AD6F-E72721B9FBACQ33982056-1D854763-7F4C-4B04-BFA2-447C38929E15Q33998654-A0AB692E-FBC7-45EF-8AA6-B6ECEF49E75FQ34065800-10DE3E07-2006-4CCD-A909-79612A3BB0A8Q34067437-985565C6-C0C2-443B-A6A6-5BBFBA1BB624Q34144064-DD3F69F0-B086-4E3E-9CFA-4B0B99114799Q34326516-F200CD41-1F30-4026-8438-89901B28163BQ34340138-C9D09E5B-96A1-4FDF-B4D3-42FF5F06DAACQ34341001-9F384A3D-F1EB-45F6-BCC8-3E5F898FEF7DQ34379476-99B2874E-279E-4FFF-A5A6-69DFCBDFA15CQ34430963-324FCA7A-6572-4C6C-8B63-6FA7B96BD5B4
P2860
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Treatment of human immunodefic ...... e. AIDS Clinical Trials Group.
@en
Treatment of human immunodefic ...... e. AIDS Clinical Trials Group.
@nl
type
label
Treatment of human immunodefic ...... e. AIDS Clinical Trials Group.
@en
Treatment of human immunodefic ...... e. AIDS Clinical Trials Group.
@nl
prefLabel
Treatment of human immunodefic ...... e. AIDS Clinical Trials Group.
@en
Treatment of human immunodefic ...... e. AIDS Clinical Trials Group.
@nl
P2093
P1476
Treatment of human immunodefic ...... e. AIDS Clinical Trials Group.
@en
P2093
Bassett RL
Collier AC
Friedman HM
McAuliffe VJ
P304
P356
10.1056/NEJM199604183341602
P407
P577
1996-04-01T00:00:00Z